Swainston Harrison Tracy, Keating Gillian M
Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 1311, New Zealand.
CNS Drugs. 2005;19(1):65-89. doi: 10.2165/00023210-200519010-00008.
Zolpidem (Ambien, Stilnox, Myslee, an imidazopyridine, is a nonbenzodiazepine hypnotic indicated for the short-term treatment of insomnia. Zolpidem improves sleep in patients with insomnia. Its overall tolerability is favourable when administered according to the manufacturer's prescribing information, with a low propensity to cause clinical residual effects, withdrawal, dependence or tolerance. In addition, most evidence suggests that the drug is associated with minimal rebound insomnia. In the only clinical trials that investigated the use of a hypnosedative drug in an 'as-needed' regimen, zolpidem produced a global improvement in sleep. Thus, zolpidem continues to be a useful therapeutic option in the pharmacological treatment of patients with insomnia.
唑吡坦(安必恩、思诺思、美时玉,一种咪唑并吡啶类药物,是一种非苯二氮䓬类催眠药,用于失眠的短期治疗。唑吡坦可改善失眠患者的睡眠。按照制造商的处方信息给药时,其总体耐受性良好,引起临床残留效应、戒断、依赖或耐受性的倾向较低。此外,大多数证据表明该药物与最小程度的反弹性失眠有关。在唯一一项研究催眠镇静药物“按需”治疗方案使用情况的临床试验中,唑吡坦使睡眠得到全面改善。因此,唑吡坦仍然是失眠患者药物治疗中的一种有用的治疗选择。